OPKO Health, Inc. Disposal Group, Including Discontinued Operation, Liabilities, Current
OPKO Health, Inc. (OPK) had Disposal Group, Including Discontinued Operation, Liabilities, Current of $8.87 million as of 2024-06-30, per its 10-Q filed 2024-08-07.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent · last filed 2024-08-07
- 2024-06-30: Disposal Group, Including Discontinued Operation, Liabilities, Current $8.87M.
- 2024-03-31: Disposal Group, Including Discontinued Operation, Liabilities, Current $9.68M.
- 2023-12-31: Disposal Group, Including Discontinued Operation, Liabilities, Current $0.00.
- 2022-12-31: Disposal Group, Including Discontinued Operation, Liabilities, Current $0.00.
| Period end | Disposal Group, Including Discontinued Operation, Liabilities, Current |
|---|---|
| 2024-06-30 | $8.87M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $9.68M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $0.00 10-Q · filed 2024-08-07 |
| 2022-12-31 | $0.00 10-K · filed 2023-02-27 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-08 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 |
| 2022-03-31 | $28.51M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $28.16M 10-K · filed 2023-02-27 |
| 2021-06-30 | $233.00K 10-Q · filed 2021-07-29 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-01 |
| 2012-09-30 | $1.00K 10-Q · filed 2012-11-09 |
| 2012-06-30 | $87.00K 10-Q · filed 2012-08-09 |
| 2012-03-31 | $245.00K 10-Q · filed 2012-05-10 |
| 2011-12-31 | $174.00K 10-K · filed 2013-03-18 |
| 2011-09-30 | $1.46M 10-Q · filed 2011-11-09 |
| 2010-12-31 | $3.06M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |